{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:17:58Z","timestamp":1792592278781,"version":"4.5.0"},"reference-count":39,"publisher":"American Association for Cancer Research (AACR)","issue":"9","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Despite the unprecedented clinical activity of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib in mantle cell lymphoma (MCL), acquired resistance is common. By longitudinal integrative whole-exome and whole-transcriptome sequencing and targeted sequencing, we identified the first relapse-specific C481S mutation at the ibrutinib binding site of BTK in MCL cells at progression following a durable response. This mutation enhanced BTK and AKT activation and tissue-specific proliferation of resistant MCL cells driven by CDK4 activation. It was absent, however, in patients with primary resistance or progression following transient response to ibrutinib, suggesting alternative mechanisms of resistance. Through synergistic induction of PIK3IP1 and inhibition of PI3K\u2013AKT activation, prolonged early G1 arrest induced by PD 0332991 (palbociclib) inhibition of CDK4 sensitized resistant lymphoma cells to ibrutinib killing when BTK was unmutated, and to PI3K inhibitors independent of C481S mutation. These data identify a genomic basis for acquired ibrutinib resistance in MCL and suggest a strategy to override both primary and acquired ibrutinib resistance.<\/jats:p>\n                  <jats:p>Significance: We have discovered the first relapse-specific BTK mutation in patients with MCL with acquired resistance, but not primary resistance, to ibrutinib, and demonstrated a rationale for targeting the proliferative resistant MCL cells by inhibiting CDK4 and the cell cycle in combination with ibrutinib in the presence of BTKWT or a PI3K inhibitor independent of BTK mutation. As drug resistance remains a major challenge and CDK4 and PI3K are dysregulated at a high frequency in human cancers, targeting CDK4 in genome-based combination therapy represents a novel approach to lymphoma and cancer therapy. Cancer Discov; 4(9); 1022\u201335. \u00a92014 AACR.<\/jats:p>\n                  <jats:p>This article is highlighted in the In This Issue feature, p. 973<\/jats:p>","DOI":"10.1158\/2159-8290.cd-14-0098","type":"journal-article","created":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T08:39:53Z","timestamp":1406882393000},"page":"1022-1035","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":260,"title":["Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S\n                    <i>BTK<\/i>\n                    Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma"],"prefix":"10.1158","volume":"4","author":[{"given":"David","family":"Chiron","sequence":"first","affiliation":[{"name":"1Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Di Liberto","sequence":"additional","affiliation":[{"name":"1Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Martin","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangao","family":"Huang","sequence":"additional","affiliation":[{"name":"1Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Sharman","sequence":"additional","affiliation":[{"name":"3Willamette Valley Cancer Institute and Research Center\/US Oncology Research, Springfield, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Blecua","sequence":"additional","affiliation":[{"name":"4Department of Physiology and Biophysics, Weill Cornell Medical College, New York, New York."},{"name":"5Institute for Computational Biomedicine, Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Mathew","sequence":"additional","affiliation":[{"name":"1Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Vijay","sequence":"additional","affiliation":[{"name":"4Department of Physiology and Biophysics, Weill Cornell Medical College, New York, New York."},{"name":"6Tri-Institutional Training Program in Computational Biology and Medicine, Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Eng","sequence":"additional","affiliation":[{"name":"4Department of Physiology and Biophysics, Weill Cornell Medical College, New York, New York."},{"name":"6Tri-Institutional Training Program in Computational Biology and Medicine, Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siraj","family":"Ali","sequence":"additional","affiliation":[{"name":"7Foundation Medicine, Inc., Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Johnson","sequence":"additional","affiliation":[{"name":"8Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty","family":"Chang","sequence":"additional","affiliation":[{"name":"9Pharmacyclics, Sunnyvale, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Ely","sequence":"additional","affiliation":[{"name":"1Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Elemento","sequence":"additional","affiliation":[{"name":"4Department of Physiology and Biophysics, Weill Cornell Medical College, New York, New York."},{"name":"5Institute for Computational Biomedicine, Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher E.","family":"Mason","sequence":"additional","affiliation":[{"name":"4Department of Physiology and Biophysics, Weill Cornell Medical College, New York, New York."},{"name":"5Institute for Computational Biomedicine, Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Leonard","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selina","family":"Chen-Kiang","sequence":"additional","affiliation":[{"name":"1Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York."},{"name":"10Graduate Program in Immunology and Microbial Pathogenesis, Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2014,9,1]]},"reference":[{"key":"2022060701085128900_bib1","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","article-title":"Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era.","volume":"117","author":"Perez-Galan","year":"2011","journal-title":"Blood"},{"key":"2022060701085128900_bib2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1600-065X.2008.00741.x","article-title":"Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain.","volume":"228","author":"Mohamed","year":"2009","journal-title":"Immunol Rev"},{"key":"2022060701085128900_bib3","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1542\/peds.9.6.722","article-title":"Agammaglobulinemia.","volume":"9","author":"Bruton","year":"1952","journal-title":"Pediatrics"},{"key":"2022060701085128900_bib4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nrd3937","article-title":"Targeting pathological B cell receptor signalling in lymphoid malignancies.","volume":"12","author":"Young","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"2022060701085128900_bib5","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060701085128900_bib6","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"2022060701085128900_bib7","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"key":"2022060701085128900_bib8","doi-asserted-by":"crossref","first-page":"OF1","DOI":"10.1158\/2159-8290.CD-NB2013-172","article-title":"Ibrutinib approved for mantle cell lymphoma.","volume":"4","year":"2014","journal-title":"Cancer Discov"},{"key":"2022060701085128900_bib9","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/blood-2007-10-117010","article-title":"Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group.","volume":"111","author":"Determann","year":"2008","journal-title":"Blood"},{"key":"2022060701085128900_bib10","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1158\/1535-7163.1427.3.11","article-title":"Specific inhibition of cyclin-dependent kinase 4\/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.","volume":"3","author":"Fry","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"2022060701085128900_bib11","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1182\/blood-2011-10-388298","article-title":"Selective CDK4\/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.","volume":"119","author":"Leonard","year":"2012","journal-title":"Blood"},{"key":"2022060701085128900_bib12","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1158\/2159-8290.CD-NB2014-053","article-title":"Palbociclib Ups PFS in HER2\u2212\/ER+ breast cancer.","volume":"4","year":"2014","journal-title":"Cancer Discov"},{"key":"2022060701085128900_bib13","doi-asserted-by":"crossref","first-page":"7661","DOI":"10.1158\/0008-5472.CAN-06-1098","article-title":"A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4\/6.","volume":"66","author":"Baughn","year":"2006","journal-title":"Cancer Res"},{"key":"2022060701085128900_bib14","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1182\/blood-2012-03-415984","article-title":"Prolonged early G(1) arrest by selective CDK4\/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4.","volume":"120","author":"Huang","year":"2012","journal-title":"Blood"},{"key":"2022060701085128900_bib15","doi-asserted-by":"crossref","first-page":"5519","DOI":"10.1158\/0008-5472.CAN-07-6404","article-title":"A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model.","volume":"68","author":"Menu","year":"2008","journal-title":"Cancer Res"},{"key":"2022060701085128900_bib16","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.4161\/cc.24928","article-title":"Induction of prolonged early G1 arrest by CDK4\/CDK6 inhibition reprograms lymphoma cells for durable PI3Kdelta inhibition through PIK3IP1.","volume":"12","author":"Chiron","year":"2013","journal-title":"Cell Cycle"},{"key":"2022060701085128900_bib17","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1073\/pnas.0510441103","article-title":"Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma.","volume":"103","author":"Greiner","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060701085128900_bib18","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1182\/blood-2013-01-478834","article-title":"The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma.","volume":"121","author":"Meissner","year":"2013","journal-title":"Blood"},{"key":"2022060701085128900_bib19","doi-asserted-by":"crossref","first-page":"18250","DOI":"10.1073\/pnas.1314608110","article-title":"Landscape of somatic mutations and clonal evolution in mantle cell lymphoma.","volume":"110","author":"Bea","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060701085128900_bib20","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nm.3435","article-title":"Pharmacological and genomic profiling identifies NF-kappaB-targeted treatment strategies for mantle cell lymphoma.","volume":"20","author":"Rahal","year":"2014","journal-title":"Nat Med"},{"key":"2022060701085128900_bib21","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1182\/blood-2013-07-517177","article-title":"The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells.","volume":"123","author":"Zhang","year":"2014","journal-title":"Blood"},{"key":"2022060701085128900_bib22","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1091\/mbc.e09-05-0387","article-title":"mTrs130 is a component of a mammalian TRAPPII complex, a Rab1 GEF that binds to COPI-coated vesicles.","volume":"20","author":"Yamasaki","year":"2009","journal-title":"Mol Biol Cell"},{"key":"2022060701085128900_bib23","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"key":"2022060701085128900_bib24","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.1073\/pnas.94.9.4330","article-title":"P110delta, a novel phosphoinositide 3-kinase in leukocytes.","volume":"94","author":"Vanhaesebroeck","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060701085128900_bib25","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1182\/blood-2013-02-482125","article-title":"Egress of CD19+CD5+ cells into peripheral blood following treatment with the BTK inhibitor ibrutinib in mantle cell lymphoma patients.","volume":"122","author":"Chang","year":"2013","journal-title":"Blood"},{"key":"2022060701085128900_bib26","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bbrc.2007.04.096","article-title":"PI3K is negatively regulated by PIK3IP1, a novel p110 interacting protein.","volume":"358","author":"Zhu","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"2022060701085128900_bib27","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1126\/science.283.5400.393","article-title":"Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha.","volume":"283","author":"Fruman","year":"1999","journal-title":"Science"},{"key":"2022060701085128900_bib28","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.cell.2009.08.041","article-title":"PI3 kinase signals BCR-dependent mature B cell survival.","volume":"139","author":"Srinivasan","year":"2009","journal-title":"Cell"},{"key":"2022060701085128900_bib29","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1182\/blood-2010-02-271171","article-title":"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.","volume":"116","author":"Herman","year":"2010","journal-title":"Blood"},{"key":"2022060701085128900_bib30","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","article-title":"The phosphoinositide 3\u2032-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.","volume":"118","author":"Hoellenriegel","year":"2011","journal-title":"Blood"},{"key":"2022060701085128900_bib31","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","article-title":"CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.","volume":"117","author":"Lannutti","year":"2011","journal-title":"Blood"},{"key":"2022060701085128900_bib32","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1158\/1535-7163.MCT-12-0993-T","article-title":"BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110alpha and p110delta activities in tumor cell lines and xenograft models.","volume":"12","author":"Liu","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"2022060701085128900_bib33","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.1021\/jm800295d","article-title":"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer.","volume":"51","author":"Folkes","year":"2008","journal-title":"J Med Chem"},{"key":"2022060701085128900_bib34","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/ng.2558","article-title":"Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia.","volume":"45","author":"Meyer","year":"2013","journal-title":"Nat Genet"},{"key":"2022060701085128900_bib35","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1182\/blood-2008-07-170183","article-title":"Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling.","volume":"113","author":"Bea","year":"2009","journal-title":"Blood"},{"key":"2022060701085128900_bib36","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/ni.2688","article-title":"MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma.","volume":"14","author":"Ying","year":"2013","journal-title":"Nat Immunol"},{"key":"2022060701085128900_bib37","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1158\/2159-8290.CD-13-0063","article-title":"What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway.","volume":"3","author":"Klempner","year":"2013","journal-title":"Cancer Discov"},{"key":"2022060701085128900_bib38","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nature13079","article-title":"Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus.","volume":"508","author":"Liu","year":"2014","journal-title":"Nature"},{"key":"2022060701085128900_bib39","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1084\/jem.184.1.31","article-title":"A role for Bruton's tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase C-gamma 2.","volume":"184","author":"Takata","year":"1996","journal-title":"J Exp Med"}],"updated-by":[{"DOI":"10.1158\/2159-8290.cd-19-1135","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000}}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/4\/9\/1022\/1839519\/1022.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/4\/9\/1022\/1839519\/1022.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T13:43:32Z","timestamp":1689428612000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/4\/9\/1022\/6452\/Cell-Cycle-Reprogramming-for-PI3K-Inhibition"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,1]]},"references-count":39,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2014,9,1]]},"published-print":{"date-parts":[[2014,9,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-14-0098","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2159-8290.22532131","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532149.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532143","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532134","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532146","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532137","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532131.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532149","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532152.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532140","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532152","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532137.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532143.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.c.6546637","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.c.6546637.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532146.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532134.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532140.v1","asserted-by":"object"}],"has-review":[{"id-type":"doi","id":"10.3410\/f.718516694.793506944","asserted-by":"object"}]},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,1]]}}}